title: The contemporary management of intracranial atherosclerotic disease.
abstract: Intracranial atherosclerotic disease is the most common cause of cerebral vasculopathy and an important stroke etiology worldwide, with a higher prevalence in Asian, Hispanic and African ethnicities. Symptomatic intracranial atherosclerotic disease portends a recurrent stroke risk as high as 18% at one year. The key to secondary prevention is an understanding of the underlying stroke mechanism and aggressive control of conventional cardiovascular risks. Contemporary treatment includes antiplatelet therapy, optimal glycemic and blood pressure control, statin therapy and lifestyle modifications. For patients with high-grade (70-99%) symptomatic steno-occlusion, short-term dual antiplatelet therapy with aspirin and clopidogrel followed by life-long single antiplatelet therapy may reduce the recurrent risk. Current evidence does not advocate percutaneous transluminal angioplasty and stenting as an initial treatment. External counterpulsation, encephaloduroarteriosynangiosis and remote limb ischemic preconditioning are treatments under investigation. Future studies should aim at predicting patients prone to recurrence despite of medical therapies and testing the efficacy of emerging therapies.
authors.affiliation: a Department of Medicine & Therapeutics , The Chinese University of Hong Kong , Hong Kong SAR , China.
authors.forename: Xinyi
authors.initials: X
authors.lastname: Leng
authors.affiliation: a Department of Medicine & Therapeutics , The Chinese University of Hong Kong , Hong Kong SAR , China.
authors.forename: Ka Sing
authors.initials: KS
authors.lastname: Wong
authors.affiliation: a Department of Medicine & Therapeutics , The Chinese University of Hong Kong , Hong Kong SAR , China.
authors.forename: Thomas W
authors.initials: TW
authors.lastname: Leung
mesh_terms: D017130:Angioplasty; D001241:Aspirin / Q000627:therapeutic use; D000077144:Clopidogrel; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D002537:Intracranial Arteriosclerosis / Q000150:complications / Q000188:drug therapy*; D020521:Stroke / Q000209:etiology / Q000517:prevention & control; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use*
chemical_list: D005343:Fibrinolytic Agents; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin
keywords: Intracranial atherosclerotic disease; anticoagulation; antiplatelet; percutaneous transluminal angioplasty and stenting; recurrence; stroke; treatment